Pharmacokinetics of single and repeated oral doses of prucalopride in healthy Chinese volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 11, 2012, Pages 797-804

  Chen, Xia ^a   Jiang, Ji ^a   Liu, Tao ^a   Liu, HongZhong ^a   Zhong, Wen ^a   Hu, Pei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Chinese; Constipation; Pharmacokinetics; Prucalopride

Indexed keywords

PRUCALOPRIDE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CAUCASIAN; CHINESE; CONSTIPATION; CONTROLLED STUDY; DEFECATION; DEFECATION HABIT; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FECES ANALYSIS; FEMALE; GASTROINTESTINAL MOTILITY; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INCIDENCE; KIDNEY CLEARANCE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NORMAL HUMAN; PHARMACOKINETICS; PHARYNGITIS; POLLAKISURIA; REPEATED DRUG DOSE; RISK ASSESSMENT; SINGLE DRUG DOSE; SKIN EXFOLIATION; STEADY STATE; TABLET FORMULATION; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BENZOFURANS; CHINA; DEFECATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; SEROTONIN 5-HT4 RECEPTOR AGONISTS; SEX FACTORS; TABLETS; YOUNG ADULT;

EID: 84867903411     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201769     Document Type: Article

References (27)

1. Manabe N, Wong BS, Camilleri M. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs. 2010; 19: 765-775. doi:10.1517/13543784.2010.482927 PubMed
2. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008; 358: 2344-2354. PubMed (Pubitemid 351749158)
3. Mendzelevski B, Ausma J, Chanter DO, Robinson P, Kerstens R, Vandeplassche L, Camm J. Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study. Br J Clin Pharmacol. 2012; 73: 203-209. doi:10.1111/j.1365- 2125.2011.04088.x PubMed
4. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009; 58: 357-365. doi:10.1136/gut.2008.162404 PubMed
5. Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut. 1999; 44: 682-686. doi:10.1136/gut.44.5.682 PubMed (Pubitemid 29195916)
6. De Schryver AM, Andriesse GI, Samsom M, Smout AJ, Gooszen HG, Akkermans LM. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther. 2002; 16: 603-612. PubMed (Pubitemid 34214542)
7. Camilleri M, Deiteren A. Prucalopride for constipation. Expert Opin Pharmacother. 2010; 11: 451-461. doi:10.1517/14656560903567057 PubMed
8. Tack J. Prucalopride: a new drug for the treatment of chronic constipation. Expert Rev Gastroenterol Hepatol. 2009; 3: 337-343. doi:10.1586/egh.09.38 PubMed
9. Lacy BE, Loew B, Crowell MD. Prucalopride for chronic constipation. Drugs Today (Barc). 2009; 45: 843-853. PubMed
10. Coremans G. Prucalopride: the evidence for its use in the treatment of chronic constipation. Core Evid. 2008; 3: 45-54. PubMed
11. Frampton JE. Prucalopride. Drugs 2009; 69: 2463-2476. PubMed
12. Emmanuel AV, Kamm MA, Roy AJ, Antonelli K. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut. 1998; 42: 511-516. doi:10.1136/gut.42.4.511 PubMed (Pubitemid 28186568)
13. Nakashima K, Narukawa M, Kanazu Y, Takeuchi M. Differences between Japan and the United States in dosages of drugs recently approved in Japan. J Clin Pharmacol. 2011; 51: 549-560. doi:10.1177/0091270010375958 DOI: 10.1177/0091270010375958 PubMed
14. Chen ML. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2006; 45: 957-964. PubMed
15. Johnson JA. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int J Clin Pharmacol Ther. 2000; 38: 53-60. PubMed (Pubitemid 30077979)
16. Resolor (Prucalopride). [Summary of Product Characteristics]. Turnhout, Belgium: Shire-Movetis NV, 2011.
17. Van de Velde V, Ausma J, Vandeplassche L. Pharmacokinetics of prucalopride (Resolor®) in man. Proceedings of the 16th United European Gastroenterology Week Congress; 2008 Oct 18-22; Vienna, Austria. Available from URL: http://uegw08.uegf.org/scienpro/abstract-detail.php?navId=139&ss=1737 [Accessed 2011 Sep27]
18. Chaplin S, Blaker P, Wilkinson M. Prucalopride (Resolor): new treatment for chronic constipation. Prescriber 2010; 5: 27-28.
19. Van de Velde VJ, Ausma J, Vandeplassche L. S1330 Comparative Pharmacokinetics of Prucalopride in Healthy Young and Elderly Subjects. Gastroenterology. 2010; 138: S-230. doi:10.1016/S0016-5085(10)61046-3
20. Stewart WF, Wood C, Reed ML, Roy J, Lipton RB; AMPP Advisory Group. Cumulative lifetime migraine incidence in women and men. Cephalalgia 2008. London.
21. Camilleri M, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil. 2009; 21: 1256-e1117. PubMed
22. Van de Velde VJ, Ausma J, Vandeplassche L. S1331 I.V. Kinetics and Absolute Oral Bioavailability of Prucalopride. Gastroenterology. 2010; 138: S-230. doi:10.1016/S0016-5085(10)61047-5
23. ICH harmonized tripartite guideline E5 (R1). Ethnic Factors in the Acceptability of Foreign Clinical Data; 5 February 1998. Available from URL: http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/ ethnic-factors-in-the-acceptability- of-foreign-clinical-data.html [Accessed 2011 Sep27].
24. Poen AC, Felt-Bersma RJ, Van Dongen PA, Meuwissen SG. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther. 1999; 13: 1493-1497. doi:10.1046/j.1365-2036.1999.00629.x PubMed (Pubitemid 29516262)
25. Prins NH, Van Haselen JFWR, Lefebvre RA, Briejer MR, Akkermans LMA, Schuurkes JAJ. Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br J Pharmacol. 1999; 127: 1431-1437. doi:10.1038/sj.bjp.0702665 PubMed (Pubitemid 29358944)
26. De Maeyer JH, Schuurkes JAJ, Lefebvre RA. Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach. Br J Pharmacol. 2009; 156: 362-376. doi:10.1111/j.1476-5381.2008.00007.x PubMed
27. Camilleri M, Van Outryve MJ, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies. Aliment Pharmacol Ther. 2010; 32: 1113-1123. doi:10.1111/j.1365-2036.2010.04455.x PubMed